false
--12-31
0001618835
0001618835
2026-11-18
2026-11-18
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
PURSUANT
TO SECTION 13 OR 15(d) OF THE
SECURITIES
EXCHANGE ACT OF 1934
Date
of Report (Date of earliest event reported): November 18, 2026
EVOFEM
BIOSCIENCES, INC.
(Exact
name of registrant as specified in its charter)
| Delaware |
|
001-36754 |
|
20-8527075 |
| (State
or other jurisdiction |
|
(Commission |
|
(I.R.S.
Employer |
| of
incorporation) |
|
File
Number) |
|
Identification
No.) |
7770
Regents Road, Suite 113-618
San
Diego, California 92122
(Address
of principal executive offices)
(858)
550-1900
(Registrant’s
telephone number, including area code)
N/A
(Former
name or former address, if changed since last report)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the Registrant under
any of the following provisions:
| ☐ |
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| |
|
| ☐ |
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a -12) |
| |
|
| ☐ |
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d -2(b)) |
| |
|
| ☐ |
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e -4(c)) |
Securities
registered pursuant to Section 12(b) of the Act:
| Title
of each class |
|
Trading
Symbol(s) |
|
Name
of exchange on which registered |
| None |
|
|
|
|
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging Growth Company ☐
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item
5.03. Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
At
the Annual Meeting of Evofem Biosciences, Inc. (the “Company”) held on November 26, 2025 (the “Annual Meeting”),
the Company’s shareholders approved an amendment to the Company’s Amended and Restated Certificate of Incorporation (the
“Certificate of Amendment”), as amended, to effect a one-time reverse stock split of the Company’s Common Stock, to
effectuate a reverse stock split of the outstanding shares of the Company’s common stock by a ratio of not less than 1-for-500
and not more than 1-for-1,500 at any time on or prior to November 26, 2026, with the exact ratio to be set at a whole number within such
range by the Company’s board of directors (the “Board”), at the sole discretion of the Company (the “Reverse
Stock Split”). The Company determined it was in the best interest of the Company to effect a reverse split at a ratio of 1-for-1,500.
The Company’s total authorized Common Stock remains unchanged.
On
November 5, 2026, the Company filed with the Secretary of State of the State of Delaware the Certificate of Amendment to effectuate the
Reverse Stock Split at a ratio of 1-for-1,500, in accordance with the General Corporation Law of the State of Delaware, effective upon
effectiveness of the Certificate of Amendment. On November 17, 2026, the Company filed with the Secretary of State of the State of Delaware
a Certificate of Correction (the “Certificate of Correction”) to change the effective time of the Reverse Stock Split from
November 5, 2026 to November 18, 2026. As a result, the Reverse Stock Split become effective upon the open of trading on the OTCID on
November 18, 2026 (the “Effective Time”). The Company’s Common Stock will trade on the OTCID under the symbol “EVFMD”,
and after twenty (20) business days, the Company’s Common Stock will continue to trade on the OTCID under the symbol “EVFM.
“ The new CUSIP number for the common stock following the Reverse Stock Split is 30048L401.
At
the Effective Time, every 1,500 shares of the Company’s issued and outstanding Common Stock (and such shares held in treasury)
was automatically converted into one share of Common Stock, without any change in the par value per share. In addition, proportionate
adjustments will be made to the per share exercise price and the number of shares issuable upon the exercise of all outstanding stock
options, stock appreciation rights, convertible notes and warrants to purchase shares of Common Stock, the number of shares issuable
upon the vesting of all restricted stock awards, and the number of shares of Common Stock reserved for issuance pursuant to the Company’s
equity incentive compensation plans. Any stockholder who was otherwise be entitled to a fractional share of Common Stock created
as a result of the Reverse Stock Split shall be entitled to receive a cash payment equal to the product of such resulting fractional
interest in one share of Common Stock multiplied by the closing trading price of the Common Stock on the trading day immediately preceding
the Effective Time, which was $0.0043.
The
above descriptions of the Certificate of Amendment, the Certificate of Correction, and the Reverse Stock Split is qualified in its entirety
by reference to the Certificate of Amendment and Certificate of Correction, copies of which are attached hereto as Exhibits 3.1 and 3.2,
respectively, and incorporated herein by reference.
Item
7.01. Regulation FD Disclosure
On
November 18, 2026, the Company issued a press release announcing the above referenced Reverse Stock Split. A copy of the press release
is furnished as Exhibit 99.1 to this Current Report on Form 8 -K.
The
information set forth under Item 7.01 of this Current Report on Form 8 -K (this “Current Report”), including
Exhibit 99. 1 attached hereto, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities
Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of such section. The information
in Item 7. 01 of this Current Report, including Exhibit 99.1, shall not be deemed incorporated by reference into any filing under the
Securities Act of 1933, as amended, or the Exchange Act, regardless of any incorporation by reference language in any such filing, except
as expressly set forth by specific reference in such a filing. This Current Report will not be deemed an admission as to the materiality
of any information in this Current Report that is required to be disclosed solely by Regulation FD.
Forward-looking
statements in this Current Report, including Exhibit 99. 1 attached hereto, or hereafter, including in other publicly available documents
filed with the Securities and Exchange Commission (“Commission”), reports to the stockholders of the Company and other publicly
available statements issued or released by us involve known and unknown risks, uncertainties and other factors which could cause our
actual results, performance (financial or operating), or achievements to differ from the future results, performance (financial or operating),
or achievements expressed or implied by such forward-looking statements. Such future results are based upon the Company’s best
estimates based upon current conditions and the most recent results of operations. These risks include, but are not limited to, the risks
associated with the Reverse Stock Split and the risks set forth in such other documents filed with the Commission, each of which could
adversely affect our business and the accuracy of the forward-looking statements contained herein. Our actual results, performance or
achievements may differ materially from those expressed or implied by such forward-looking statements.
Item
9.01. Financial Statements and Exhibits
(d)
Exhibits
| Exhibit
No. |
|
Description |
| 3.1 |
|
Certificate of Amendment to the Amended and Restated Certificate of Incorporation of Evofem Biosciences, Inc., filed November 5, 2026 |
| 3.2 |
|
Certificate of Correction, filed November 17, 2026 |
| 99.1 |
|
Press Release dated November 18, 2026 |
| 104 |
|
Cover
Page Interactive Data File (embedded within the Inline XBRL document). |
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
| |
EVOFEM
BIOSCIENCES, INC. |
| |
|
| Dated:
November 18, 2026 |
By: |
/s/
Saundra Pelletier |
| |
|
Saundra
Pelletier |
| |
|
Chief
Executive Officer |
Exhibit
99.1

Evofem
Biosciences Effects Previously-Approved
Reverse
Stock Split
—
CUSIP number for Evofem will change to 30048L401 on November 18, 2026 —
—
Ticker symbol will change to “EVFMD” for 20 business days, then revert to “EVFM” —
SAN
DIEGO, CA, November 18, 2026 — Women’s health innovator Evofem Biosciences, Inc. (OTCID: EVFM) today announced a 1-for-1,500
reverse stock split of the Company’s common stock, which was approved by the stockholders of the Company at the Annual Meeting
of Stockholders held on November 26, 2025.
| ● | On
Wednesday November 18, 2026, the Company’s common stock will open for trading under
a new CUSIP (30048L401) on the OTC Basic Market, on a split-adjusted basis, under the ticker
symbol “EVFMD.” |
| ● | After
20 business days, the ticker symbol will change back to “EVFM.” |
The
reverse stock split is intended to ensure the Company has enough authorized shares of common stock to cover the number of common shares
underlying the Company’s financial instruments on a fully diluted basis.
The
1-for-1,500 reverse stock split will automatically convert 1,500 current shares of the Company’s common stock into one share of
common stock. No fractional shares will be issued in connection with the reverse stock split. Stockholders who would otherwise hold a
fractional share of the Company’s common stock will receive a cash payment in lieu thereof at a price equal to that fraction to
which the stockholder would otherwise be entitled multiplied by the closing trading price of the common stock on the OTC Basic Market
on Tuesday, November 17, 2026, and rounded down to the nearest whole cent.
The
reverse split will reduce the number of shares of outstanding common stock from approximately 132,530,081 shares, the number of shares
outstanding as of November 17, 2026, which was the Record Date for this transaction, to approximately 88,353 shares. Proportional adjustments
will be made to the exercise and conversion prices of the Company’s outstanding stock options, warrants, purchase rights, and convertible
notes, and to the number of shares issued and issuable under the Company’s stock incentive plans.
Stockholders
holding their shares electronically in book-entry form are not required to take any action to receive post-split shares. Stockholders
owning shares through a bank, broker or other nominee will have their positions automatically adjusted to reflect the reverse stock split,
subject to brokers’ particular processes, and will not be required to take any action in connection with the reverse stock split.
For those stockholders holding physical stock certificates, the Company’s transfer agent, Pacific Stock Transfer, will send instructions
for exchanging those certificates for shares held electronically in book-entry form or for new certificates, in either case representing
the post-split number of shares, and any payments in cash in lieu of fractional shares, if applicable.
About
Evofem Biosciences, Inc.
Evofem
Biosciences is a San Diego-based pharmaceutical company commercializing two FDA-approved sexual and reproductive health products:
| ● | PHEXX®
(lactic acid, citric acid, and potassium bitartrate) – the first and only hormone-free,
on-demand prescription contraceptive vaginal gel. Visit phexx.com to learn more and for important
safety information. |
| ● | SOLOSEC®
(secnidazole) 2g oral granules – an FDA-approved oral antibiotic for the treatment
of two sexual health diseases: bacterial vaginosis (BV), a common vaginal infection, in females
12 years of age and older, and trichomoniasis, a common sexually transmitted infection (STI),
in people 12 years of age and older. SOLOSEC provides a complete course of therapy in just
one dose. Visit solosec.com to learn more and for important safety information. |
PHEXX®
and SOLOSEC® are registered trademarks of Evofem Biosciences, Inc.
Contact
Amy
Raskopf
Evofem
Biosciences, Inc.
araskopf@evofem.com
(917)
673-5775
###